{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:57:10Z","timestamp":1794376630598,"version":"4.9.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-77847-9","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T11:15:17Z","timestamp":1789816517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The EF1\u03b1 promoter of cilta-cel drives a highly effective GZMK+ transcriptional program"],"prefix":"10.1038","volume":"17","author":[{"given":"Kevin","family":"Herrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7718-8721","authenticated-orcid":false,"given":"Sneha","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Lucero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin A.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meril","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-0456","authenticated-orcid":false,"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2903-5130","authenticated-orcid":false,"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-8731","authenticated-orcid":false,"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4332-3291","authenticated-orcid":false,"given":"Ronan","family":"Chaligne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"de Stanchina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2815-9561","authenticated-orcid":false,"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4571-5910","authenticated-orcid":false,"given":"Christina S.","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-7596","authenticated-orcid":false,"given":"Karlo","family":"Perica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"77847_CR1","doi-asserted-by":"crossref","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"77847_CR2","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1182\/blood-2024-201533","volume":"144","author":"R Popat","year":"2024","unstructured":"Popat, R. et al. Ciltacabtagene autoleucel (Cilta-cel) vs standard of care (SoC) in patients with lenalidomide (len)-refractory multiple myeloma (MM) after 1-3 lines of therapy: minimal residual disease (MRD) negativity in the phase 3 cartitude-4 trial. Blood 144, 1032 (2024).","journal-title":"Blood"},{"key":"77847_CR3","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002\u20131014 (2023).","journal-title":"N. Engl. J. Med."},{"key":"77847_CR4","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"77847_CR5","doi-asserted-by":"crossref","unstructured":"Merz, M. et al. Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: an international multicenter study. Hemasphere 9, e70070 (2025).","DOI":"10.1002\/hem3.70070"},{"key":"77847_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/10428194.2023.2276676","volume":"65","author":"L Scheller","year":"2024","unstructured":"Scheller, L. et al. BCMA CAR-T cells in multiple myeloma\u2013ready for take-off?. Leuk. Lymphoma 65, 143\u2013157 (2024).","journal-title":"Leuk. Lymphoma"},{"key":"77847_CR7","unstructured":"Campbell, T. et al. WO2021091978A1. (2021)."},{"key":"77847_CR8","unstructured":"US20240409654A1."},{"key":"77847_CR9","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/ni1268","volume":"6","author":"AM Intlekofer","year":"2005","unstructured":"Intlekofer, A. M. et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat. Immunol. 6, 1236\u20131244 (2005).","journal-title":"Nat. Immunol."},{"key":"77847_CR10","doi-asserted-by":"crossref","unstructured":"Giles, J. R. et al. Shared and distinct biological circuits in effector, memory and exhausted CD8+ T cells revealed by temporal single-cell transcriptomics and epigenetics. Nat. Immunol. 23, 1600\u20131613 (2022).","DOI":"10.1038\/s41590-022-01338-4"},{"key":"77847_CR11","doi-asserted-by":"crossref","unstructured":"Kay Chung, H., McDonald, B. & Kaech, S. M. The architectural design of CD8+ T cell responses in acute and chronic infection: Parallel structures with divergent fates. J. Exp. Med. 218, e20201730 (2021).","DOI":"10.1084\/jem.20201730"},{"key":"77847_CR12","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1126\/science.1090148","volume":"302","author":"EL Pearce","year":"2003","unstructured":"Pearce, E. L. et al. Control of effector CD8+ T cell function by the transcription factor eomesodermin. Science 302, 1041\u20131043 (2003).","journal-title":"Science"},{"key":"77847_CR13","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.ccell.2023.03.009","volume":"41","author":"JA Pai","year":"2023","unstructured":"Pai, J. A. et al. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. Cancer Cell 41, 776\u2013790.e7 (2023).","journal-title":"Cancer Cell"},{"key":"77847_CR14","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-23-0913","volume":"14","author":"AZ Wang","year":"2024","unstructured":"Wang, A. Z. et al. Glioblastoma-infiltrating CD8+ T cells are predominantly a clonally expanded GZMK+ effector population. Cancer Discov. 14, 1106\u20131131 (2024).","journal-title":"Cancer Discov."},{"key":"77847_CR15","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ccell.2021.03.007","volume":"39","author":"C Krishna","year":"2021","unstructured":"Krishna, C. et al. Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. Cancer Cell 39, 662\u2013677.e6 (2021).","journal-title":"Cancer Cell"},{"key":"77847_CR16","doi-asserted-by":"publisher","unstructured":"Sievers, C. M. et al. GZMK expression within activated intratumoral T-cell subsets reflects differentiation efficiency and predicts response to cancer immunotherapy. npj Precis. Oncol. https:\/\/doi.org\/10.1038\/s41698-026-01437-7 (2026).","DOI":"10.1038\/s41698-026-01437-7"},{"key":"77847_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.immuni.2020.11.005","volume":"54","author":"DA Mogilenko","year":"2021","unstructured":"Mogilenko, D. A. et al. Comprehensive profiling of an aging immune system reveals clonal GZMK+ CD8+ T cells as conserved hallmark of inflammaging. Immunity 54, 99\u2013115.e12 (2021).","journal-title":"Immunity"},{"key":"77847_CR18","first-page":"686","volume":"14","author":"Helena","year":"2022","unstructured":"Helena et al. Granzyme K + CD8 T cells form a core population in inflamed human tissue. Sci. Transl. Med. 14, 686 (2022).","journal-title":"Sci. Transl. Med."},{"key":"77847_CR19","doi-asserted-by":"crossref","unstructured":"Lan, F. et al. GZMK-expressing CD8+ T cells promote recurrent airway inflammatory diseases. Nature 638, 490\u2013498 (2025).","DOI":"10.1038\/s41586-024-08395-9"},{"key":"77847_CR20","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.it.2025.06.003","volume":"46","author":"CL Guo","year":"2025","unstructured":"Guo, C. L., Wang, C. S., Wang, X. H., Yu, D. & Liu, Z. GZMK+CD8+ T cells: multifaceted roles beyond cytotoxicity. Trends Immunol. 46, 562\u2013572 (2025).","journal-title":"Trends Immunol."},{"key":"77847_CR21","doi-asserted-by":"publisher","unstructured":"Rade, M. et al. Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma. Nat. Cancer https:\/\/doi.org\/10.1038\/s43018-024-00763-8 (2024).","DOI":"10.1038\/s43018-024-00763-8"},{"key":"77847_CR22","doi-asserted-by":"crossref","unstructured":"Atanackovic, D. et al. Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma. Nat. Commun. 16, 6154 (2025).","DOI":"10.1038\/s41467-025-60980-2"},{"key":"77847_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nm.4241","volume":"23","author":"L Gattinoni","year":"2017","unstructured":"Gattinoni, L., Speiser, D. E., Lichterfeld, M. & Bonini, C. T memory stem cells in health and disease. Nat. Med. 23, 18\u201327 (2017).","journal-title":"Nat. Med."},{"key":"77847_CR24","doi-asserted-by":"crossref","unstructured":"Sun, Q. & Dong, C. Regulators of CD8+ T cell exhaustion. Nat. Rev. Immunol. 26, 129\u2013151 (2026).","DOI":"10.1038\/s41577-025-01221-x"},{"key":"77847_CR25","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s41587-021-00927-2","volume":"39","author":"EP Mimitou","year":"2021","unstructured":"Mimitou, E. P. et al. Scalable, multimodal profiling of chromatin accessibility, gene expression and protein levels in single cells. Nat. Biotechnol. 39, 1246\u20131258 (2021).","journal-title":"Nat. Biotechnol."},{"key":"77847_CR26","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41587-021-01033-z","volume":"40","author":"E Dann","year":"2022","unstructured":"Dann, E., Henderson, N. C., Teichmann, S. A., Morgan, M. D. & Marioni, J. C. Differential abundance testing on single-cell data using k-nearest neighbor graphs. Nat. Biotechnol. 40, 245\u2013253 (2022).","journal-title":"Nat. Biotechnol."},{"key":"77847_CR27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41587-019-0068-4","volume":"37","author":"M Setty","year":"2019","unstructured":"Setty, M. et al. Characterization of cell fate probabilities in single-cell data with Palantir. Nat. Biotechnol. 37, 451\u2013460 (2019).","journal-title":"Nat. Biotechnol."},{"key":"77847_CR28","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/nmeth.4401","volume":"14","author":"AN Schep","year":"2017","unstructured":"Schep, A. N., Wu, B., Buenrostro, J. D. & Greenleaf, W. J. ChromVAR: inferring transcription-factor-associated accessibility from single-cell epigenomic data. Nat. Methods 14, 975\u2013978 (2017).","journal-title":"Nat. Methods"},{"key":"77847_CR29","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41588-024-01689-8","volume":"56","author":"S Mitra","year":"2024","unstructured":"Mitra, S. et al. Single-cell multi-ome regression models identify functional and disease-associated enhancers and enable chromatin potential analysis. Nat. Genet. 56, 627\u2013636 (2024).","journal-title":"Nat. Genet."},{"key":"77847_CR30","doi-asserted-by":"publisher","first-page":"12410","DOI":"10.1073\/pnas.1905675116","volume":"116","author":"H Seo","year":"2019","unstructured":"Seo, H. et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc. Natl. Acad. Sci. USA 116, 12410\u201312415 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77847_CR31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","volume":"571","author":"AC Scott","year":"2019","unstructured":"Scott, A. C. et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571, 270\u2013274 (2019).","journal-title":"Nature"},{"key":"77847_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571, 211\u2013218 (2019).","journal-title":"Nature"},{"key":"77847_CR33","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41586-019-0979-8","volume":"567","author":"X Liu","year":"2019","unstructured":"Liu, X. et al. Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction. Nature 567, 525\u2013529 (2019).","journal-title":"Nature"},{"key":"77847_CR34","doi-asserted-by":"crossref","unstructured":"Pulvirenti, N. et al. Characterization of human CD4+EOMES+GzmK+ T-cell subsets unveils an uncoupling of suppressive functions from IL-10-producing capacities. Eur. J. Immunol. 54, e2350675 (2024).","DOI":"10.1002\/eji.202350675"},{"key":"77847_CR35","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.immuni.2019.09.013","volume":"51","author":"Z Chen","year":"2019","unstructured":"Chen, Z. et al. TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision. Immunity 51, 840\u2013855.e5 (2019).","journal-title":"Immunity"},{"key":"77847_CR36","doi-asserted-by":"crossref","unstructured":"Tiberti, S. et al. GZMKhigh CD8+ T effector memory cells are associated with CD15high neutrophil abundance in non-metastatic colorectal tumors and predict poor clinical outcome. Nat. Commun. 13, 6752 (2022).","DOI":"10.1038\/s41467-022-34467-3"},{"key":"77847_CR37","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow, A., Perica, K., Klebanoff, C. A. & Wolchok, J. D. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat. Rev. Clin. Oncol. 19, 775\u2013790 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"77847_CR38","doi-asserted-by":"publisher","first-page":"eadf1426","DOI":"10.1126\/sciimmunol.adf1426","volume":"8","author":"C He","year":"2023","unstructured":"He, C. et al. CD19 CAR antigen engagement mechanisms and affinity tuning. Sci. Immunol. 8, eadf1426 (2023).","journal-title":"Sci. Immunol."},{"key":"77847_CR39","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 1408\u20131414 (2019).","journal-title":"Nat. Med."},{"key":"77847_CR40","doi-asserted-by":"crossref","unstructured":"Jayaraman, J. et al. CAR-T design: elements and their synergistic function. EBioMedicine 58, 102931 (2020).","DOI":"10.1016\/j.ebiom.2020.102931"},{"key":"77847_CR41","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-21-0552","volume":"21","author":"JM Buonato","year":"2022","unstructured":"Buonato, J. M. et al. Preclinical efficacy of BCMA-directed CAR T cells incorporating A novel D domain antigen recognition domain. Mol. Cancer Ther. 21, 1171\u20131183 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"77847_CR42","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1182\/blood-2024-198499","volume":"144","author":"CL Freeman","year":"2024","unstructured":"Freeman, C. L. et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and\/or refractory multiple myeloma: preliminary results from the IMMagine-1 trial. Blood 144, 1031 (2024).","journal-title":"Blood"},{"key":"77847_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-025-00710-y","volume":"14","author":"W Chen","year":"2025","unstructured":"Chen, W. et al. Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed\/refractory multiple myeloma. Exp. Hematol. Oncol. 14, 1\u201314 (2025).","journal-title":"Exp. Hematol. Oncol."},{"key":"77847_CR44","doi-asserted-by":"publisher","first-page":"71.e1","DOI":"10.1016\/j.jtct.2024.12.002","volume":"31","author":"M Ellithi","year":"2025","unstructured":"Ellithi, M. et al. Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: a comprehensive analysis of real-world FAERS data. Transplant. Cell. Ther. 31, 71.e1\u201371.e14 (2025).","journal-title":"Transplant. Cell. Ther."},{"key":"77847_CR45","doi-asserted-by":"publisher","unstructured":"Sadigh, S., Armand, P., Ph, D., Uren, A. & Anderson, K. C. Indolent CD4+ CAR T-cell lymphoma after cilta-cel CAR T-cell therapy. 2074\u20132082 https:\/\/doi.org\/10.1056\/NEJMoa2401530 (2024).","DOI":"10.1056\/NEJMoa2401530"},{"key":"77847_CR46","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJMoa2411507","volume":"392","author":"K Perica","year":"2025","unstructured":"Perica, K. et al. CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53. N. Engl. J. Med. 392, 577\u2013583 (2025).","journal-title":"N. Engl. J. Med."},{"key":"77847_CR47","unstructured":"Fortuna, G. G. et al. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J. 14, 180 (2024)."},{"key":"77847_CR48","doi-asserted-by":"crossref","unstructured":"Rodriguez-Marquez, P. et al. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome. Sci. Adv. 8, eabo0514 (2022).","DOI":"10.1126\/sciadv.abo0514"},{"key":"77847_CR49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","volume":"21","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva, D. et al. Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent. Cell Rep. 21, 17\u201326 (2017).","journal-title":"Cell Rep."},{"key":"77847_CR50","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543, 113\u2013117 (2017).","journal-title":"Nature"},{"key":"77847_CR51","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 602, 503\u2013509 (2022).","journal-title":"Nature"},{"key":"77847_CR52","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"77847_CR53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00760","author":"S Jagannath","year":"2025","unstructured":"Jagannath, S. et al. Long-term (\u22655-Year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO-25-00760 (2025).","journal-title":"J. Clin. Oncol."},{"key":"77847_CR54","doi-asserted-by":"publisher","unstructured":"Granja, J. M. et al. ArchR is a scalable software package for integrative single-cell chromatin accessibility analysis. Nat. Genet. 53, 403\u2013411 https:\/\/doi.org\/10.1038\/s41588-021-00790-6 (2021).","DOI":"10.1038\/s41588-021-00790-6"},{"key":"77847_CR55","doi-asserted-by":"publisher","unstructured":"Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42, 293\u2013304 https:\/\/doi.org\/10.1038\/s41587-023-01767-y (2024).","DOI":"10.1038\/s41587-023-01767-y"},{"key":"77847_CR56","doi-asserted-by":"publisher","unstructured":"Andreatta, M. et al. Semi-supervised integration of single-cell transcriptomics data. Nat. Commun. 15, 872 https:\/\/doi.org\/10.1038\/s41467-024-45240-z (2024).","DOI":"10.1038\/s41467-024-45240-z"},{"key":"77847_CR57","doi-asserted-by":"publisher","unstructured":"Zhang, Y. et al. Model-based Analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 https:\/\/doi.org\/10.1186\/gb-2008-9-9-r137 (2008).","DOI":"10.1186\/gb-2008-9-9-r137"},{"key":"77847_CR58","doi-asserted-by":"publisher","unstructured":"Matthew, T. et al. Determination and Inference of Eukaryotic Transcription Factor Sequence Specificity. Cell 158, 1431\u20131443 https:\/\/doi.org\/10.1016\/j.cell.2014.08.009 (2014).","DOI":"10.1016\/j.cell.2014.08.009"},{"key":"77847_CR59","doi-asserted-by":"publisher","unstructured":"McLeay, R. C. & Bailey, T. L. Motif Enrichment Analysis: a unified framework and an evaluation on ChIP data. BMC Bioinformatics 11, 165 https:\/\/doi.org\/10.1186\/1471-2105-11-165 (2010).","DOI":"10.1186\/1471-2105-11-165"},{"key":"77847_CR60","doi-asserted-by":"publisher","unstructured":"Heumos, L. et al. Pertpy: an end-to-end framework for perturbation analysis. Nat. Methods 23, 350\u2013359 https:\/\/doi.org\/10.1038\/s41592-025-02909-7 (2026).","DOI":"10.1038\/s41592-025-02909-7"},{"key":"77847_CR61","doi-asserted-by":"publisher","unstructured":"Gregor Sturm, Tamas Szabo, Georgios Fotakis, Marlene Haider, Dietmar Rieder, Zlatko Trajanoski, Francesca Finotello, Scirpy: a Scanpy extension for analyzing single-cell T-cell receptor-sequencing data. Bioinformatics 36, 4817\u20134818 https:\/\/doi.org\/10.1093\/bioinformatics\/btaa611 (2020).","DOI":"10.1093\/bioinformatics\/btaa611"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77847-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77847-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77847-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:38:01Z","timestamp":1792535881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77847-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77847"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77847-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.A.G. - Personal fees and advisory board: Actinium, Celgene, BMS, Sanofi, Amgen, Pfizer, GSK, Jazz, Janssen, Omeros, Takeda, and Kite. G.L.S. - Research funding: Janssen, Amgen, BMS, Beyond Spring; serves on the data safety monitoring board (DSMB) for ArcellX; and receives research funding to the institution from Janssen, Amgen, BMS, Beyond Spring, and GPCR. J.H.P. \u2013 Professional services and activities: Adaptive Biotechnologies Corp, Affyimmune Therapeutics, Inc., Allogene Therapeutics, Amgen, Artiva Biotherapeutics, Inc., Ascentage Pharma, Autolus Therapeutics, Bright Pharmaceuticals, Bristol-Myers Squibb, Curocell Inc., Iovance Biotherapeutics, Inc., Jazz Pharmaceuticals, Kite Pharmaceuticals, Servier, and Synthekine, Inc. S.M. - Consultancy: Evicore, Optum, BioAscend, Janssen Oncology, BMS, AbbVie, HMP Education, and Legend Biotech; Honoraria: OncLive, Physician Education Resource, MJH Life Sciences, and Plexus Communications. Research funding: Janssen Oncology, BMS, Allogene Therapeutics, Fate Therapeutics, Caribou Therapeutics, and Takeda Oncology. S.Z.U. - Grants and personal fees: AbbVie, 404 Amgen, BMS, Celgene, GSK, Janssen, Merck, Mundipharma, Oncopeptides, 405 Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda. C.L. \u2013 Equity: Episteme Prognostics K.P. \u2013 Royalties: Neximmune, Grants and personal fees: RxCure, Pfizer. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10980"}}